MS159JC88:
Shares of CytomX Therapeutics (NASDAQ:CTMX) climbed the morning hours on Wednesday after the cancer drug developer fast-tracked an early stage readout from its experimental bispecific antibody, CX-904, developed in partnership with Amgen (NASDAQ:AMGN).
JC88 : Going $6
MS159 JC88: Shares of CytomX Therapeutics (NASDAQ:CTMX) climbed the morning hours on Wednesday after the cancer drug developer fast-tracked an early stage readout from its experimental bispecific antibody, CX-904, developed in partnership with Amgen (NASDAQ:AMGN).